Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2020.06.01

Ensuring manufacturing continuity during the pandemic

Ensuring manufacturing continuity during the pandemic. Together.

‘Make it better together’ is a guiding tenet for how we operate each day. Yet, as it often does during a crisis, a truly collaborative effort during the present pandemic involving all our supply partners, airline & shipping companies, freight forwarders, transporters and our own cross-functional teams, has emphatically reinforced this belief. It has allowed us to keep our supply chain intact ensuring that our manufacturing operations continued with zero downtime and enabled us to uphold our commitments to our customers.

Proactive risk identification
Anticipating the supply chain risk well before COVID-19 was declared a global pandemic, we conducted a survey covering all our partners, especially in the affected countries, to assess the risk and get a granular understanding of the extent of supply impact across various projects. This timely and detailed information helped our supply chain team develop various strategies to mitigate or minimize the impact.

Translating plans to actions
For an intense period of close to ten weeks, all our cross-functional teams and external partners sustained a 24 x 7 operating model spanning various time zones and implementing solutions in real-time. The team shifted all pending orders in highly affected zones to partners located in medium and low impact zones, by leveraging the strong relationships built over time. We also increased the share of supplies from partners located in less impacted regions. Once the materials were ready, their movement posed a considerable challenge. The team had to reroute several shipments adopting complex logistics solutions involving multi-mode, multi-continent and multi 3PL operators. We used all functional entry gateways, both airports and seaports, which were functional for both inbound and outbound shipments.

Gratifying outcome of collaborative effort
The team handled a total of 294 shipments from the start of lockdown, honouring the delivery commitment to the customers with OTIF > 97% while ensuring zero downtime in the manufacturing activity. Most importantly, the entire effort demonstrated the strength and resilience of our relationships, and an unwavering zeal to make it better together.

Share article

More News

2025.08.28

Sai Life Sciences completes Phase II of Production Block 11 at Bidar site, India, expands capacity to 700 KL

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the completion of Phase II of its new Production Block (PB-11) at the company’s flagship API manufacturing facility in Bidar, India (Unit IV). The Phase I of PB-11, with a capacity of 110 KL, was inaugurated […]
Read more

2025.08.20

Sai Life Sciences secures SBTi validation for near-term climate targets

Sai Life Sciences Limited, an innovator focused Contract Research, Development, and Manufacturing Organization (CRDMO), announced that its near-term targets to cut greenhouse gas (GHG) emissions have been validated by the Science Based Targets initiative (SBTi)—a corporate climate action organization that enables companies and financial institutions worldwide to play their part in combating the climate crisis. […]
Read more

2025.08.20

Sai Life Sciences featured in Drug Discovery & Development on trends shaping drug discovery

Sai Life Sciences was recently featured in Drug Discovery & Development, where Dr Maneesh Pingle, Executive Vice President and Head of Discovery Services, shared insights on the emerging trends in pharma sector. A key focus was the impact of GLP 1 agonists in accelerating peptide drug discovery. Dr. Pingle explained how the success of these […]
Read more

2025.08.13

Peptide Science & Beyond: Masterclass & Fireside Chat with IISc Professor, Dr. Jayanta Chatterjee

Sai Life Sciences recently hosted Dr. Jayanta Chatterjee, Associate Professor at the Indian Institute of Science (IISc), Bangalore, for two enriching sessions at its campus. The first was the Masterclass Lecture Series, where Dr. Chatterjee addressed a group of scientists at Sai Life Sciences on “Our Adventures in the de novo Design of Helical Macrocyclic […]
Read more

2025.08.13

From vendor to vanguard: Reimagining India’s role in global life sciences

In a recent article published in ET Edge titled, ‘From Vendor to Vanguard: Reimagining India’s Role in Global Life Sciences,’ Krishna Kanumuri, MD & CEO, Sai Life Sciences, highlighted India’s rapidly unfolding transformation from a vendor to an innovation leader in the global life sciences ecosystem.You can read the full article here: From vendor to vanguard: […]
Read more